NCT01392612View on ClinicalTrials.gov

Erythropoietin and Platelet Activation Markers

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

July 31, 2007

Conditions
ThrombosisHypertension
Interventions
DRUG

erythropoietin

Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT01392612 - Erythropoietin and Platelet Activation Markers | Biotech Hunter | Biotech Hunter